|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:acquisitionYear
|
2017
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focus
|
oncology
|
|
gptkbp:founded
|
1991
|
|
gptkbp:founder
|
gptkb:Harvey_J._Berger
|
|
gptkbp:headquarters_location
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Harvey_J._Berger
gptkb:Paris_Panayiotopoulos
gptkb:Timothy_P._Clackson
|
|
gptkbp:market
|
gptkb:Europe
gptkb:United_States
|
|
gptkbp:notableEvent
|
FDA approval of Iclusig (ponatinib) in 2012
|
|
gptkbp:notableProduct
|
gptkb:brigatinib
gptkb:ponatinib
|
|
gptkbp:numberOfEmployees
|
~300 (before acquisition)
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:researchArea
|
targeted cancer therapies
|
|
gptkbp:status
|
defunct
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:ARIA
|
|
gptkbp:website
|
www.ariad.com
|
|
gptkbp:bfsParent
|
gptkb:brigatinib
gptkb:Brigatinib
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ariad Pharmaceuticals
|